Literature DB >> 8645841

Concentrations of interferon gamma, tumor necrosis factor alpha, and interleukin-1 beta in the cerebrospinal fluid of children treated for tuberculous meningitis.

P R Donald1, J F Schoeman, N Beyers, E D Nel, S M Carlini, K D Olsen, G H McCracken.   

Abstract

Concentrations of interferon gamma (IFN-gamma) in the lumbar cerebrospinal fluid (CSF) of 30 children (mean age, 27 months) being treated for stage III (16 children) and stage II (14 children) tuberculosis meningitis (TBM) were determined by ELISA. Nine children with stage III TBM and six with stage II TBM received prednisone (4 mg/kg). Concentrations of IFN-gamma in 73 CSF specimens (18 from the first week of therapy, 20 from the second, 19 from the third, and 16 from the fourth) were determined. The mean concentrations were 780 pg/mL in the first week of therapy and 554 pg/mL, 529 pg/mL, and 269 pg/mL in the second, third, and fourth weeks, respectively. Tumor necrosis factor alpha (TNF-alpha) and interleukin-1beta (IL-1beta) concentrations in 56 specimens from 23 of these same children were determined by ELISA. The mean CSF TNF-alpha concentration in 12 specimens obtained during the first week of therapy was 17 pg/mL, and the mean was 11 pg/mL during each of the subsequent weeks (14 specimens were evaluated in the second week and 15 specimens in the third and fourth weeks of therapy). Mean IL-1beta concentrations in these same groups of specimens were 52 pg/mL, 43 pg/mL, 42 pg/mL, and 18 pg/mL. No correlation could be shown between cytokine concentration and stage of disease, and no differences existed between those who did and those who did not receive prednisone. A significant decline in IL-1beta concentrations was shown during the 4-week period, but none in TNF-alpha or IFN-gamma concentrations was noted. Persistently high CSF INF-gamma concentrations in cases of TBM (as in cases of aseptic meningitis but not bacterial meningitis) at the time of diagnosis suggest an immune response fundamentally different from that in bacterial meningitis.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8645841     DOI: 10.1093/clinids/21.4.924

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  18 in total

Review 1.  Tuberculous meningitis.

Authors:  G Thwaites; T T Chau; N T Mai; F Drobniewski; K McAdam; J Farrar
Journal:  J Neurol Neurosurg Psychiatry       Date:  2000-03       Impact factor: 10.154

Review 2.  Management of intracranial pressure in tuberculous meningitis.

Authors:  J M K Murthy
Journal:  Neurocrit Care       Date:  2005       Impact factor: 3.210

3.  Interferon gamma quantification in cerebrospinal fluid compared with PCR for the diagnosis of tuberculous meningitis.

Authors:  Rafael San Juan; Carmen Sánchez-Suárez; María J Rebollo; Dolores Folgueira; Elia Palenque; Blanca Ortuño; Carlos Lumbreras; José M Aguado
Journal:  J Neurol       Date:  2006-06-19       Impact factor: 4.849

4.  Use of IMiD3, a thalidomide analog, as an adjunct to therapy for experimental tuberculous meningitis.

Authors:  Liana Tsenova; Bande Mangaliso; George Muller; Yong Chen; Victoria H Freedman; David Stirling; Gilla Kaplan
Journal:  Antimicrob Agents Chemother       Date:  2002-06       Impact factor: 5.191

5.  Relationship between intracranial granulomas and cerebrospinal fluid levels of gamma interferon and interleukin-10 in patients with tuberculous meningitis.

Authors:  Adel M Mansour; Robert W Frenck; Toni Darville; Isabelle A Nakhla; Thomas F Wierzba; Yehia Sultan; Magdy I Bassiouny; Kathryn McCarthy; Richard F Jacobs
Journal:  Clin Diagn Lab Immunol       Date:  2005-02

6.  Chemokine profiles in the cerebrospinal fluid (CSF) during the course of pyogenic and tuberculous meningitis.

Authors:  C M Mastroianni; L Lancella; F Mengoni; M Lichtner; P Santopadre; C D'Agostino; F Ticca; V Vullo
Journal:  Clin Exp Immunol       Date:  1998-11       Impact factor: 4.330

7.  Corticosteroid-modulated immune activation in the tuberculosis immune reconstitution inflammatory syndrome.

Authors:  Graeme Meintjes; Keira H Skolimowska; Katalin A Wilkinson; Kerryn Matthews; Rebecca Tadokera; Anali Conesa-Botella; Ronnett Seldon; Molebogeng X Rangaka; Kevin Rebe; Dominique J Pepper; Chelsea Morroni; Robert Colebunders; Gary Maartens; Robert J Wilkinson
Journal:  Am J Respir Crit Care Med       Date:  2012-06-14       Impact factor: 21.405

8.  Reactive oxygen species and p47phox activation are essential for the Mycobacterium tuberculosis-induced pro-inflammatory response in murine microglia.

Authors:  Chul-Su Yang; Hye-Mi Lee; Ji-Yeon Lee; Jeong-Ah Kim; Sung Joong Lee; Dong-Min Shin; Young-Ho Lee; Dong-Seok Lee; Jamel El-Benna; Eun-Kyeong Jo
Journal:  J Neuroinflammation       Date:  2007-11-26       Impact factor: 8.322

Review 9.  Tuberculous Meningitis: Pathogenesis, Immune Responses, Diagnostic Challenges, and the Potential of Biomarker-Based Approaches.

Authors:  Charles M Manyelo; Regan S Solomons; Gerhard Walzl; Novel N Chegou
Journal:  J Clin Microbiol       Date:  2021-02-18       Impact factor: 5.948

10.  Influence of Strongyloides stercoralis Coinfection on the Presentation, Pathogenesis, and Outcome of Tuberculous Meningitis.

Authors:  Joseph Donovan; Trinh Thi Bich Tram; Nguyen Hoan Phu; Nguyen Thi Thu Hiep; Vu Thi Thu Van; Dang Thi Hong Mui; Nguyen Thi Han Ny; Ho Dang Trung Nghia; Nguyen Ho Hong Hanh; Le Van Tan; Nguyen Thuy Thuong Thuong; Guy E Thwaites
Journal:  J Infect Dis       Date:  2022-05-04       Impact factor: 7.759

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.